This morning $IMGN got taken out at a ~100% premium by $ABBV, I mentioned on Twitter that I think $LNTH could be acquired at some point and here's why...
Almost exactly 12 months ago $LNTH paid $260M for the distribution/commercialization rights to $PNT (Point biopharma) drugs PNT2002 and PNT2003... https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-and-point-biopharma-announce-strategic-collaboration…
SPLASH trial data for PNT2002 could be out in the next 30 days.
Two months ago $LLY acquired $PNT for $1.4 billion, I'm pretty sure they would not have done that deal if they didn't feel very good about trial data for PNT2002 and PNT2003.
If the PNT2002 trial data looks good it's a very big catalyst for $LNTH since they own the distribution/commercialization rights but that's why I think $LLY could swoop in and buy $LNTH for $135+ per share which is less than 18x my 2025 EPS estimates. Right now $LLY is trading at 34x 2025 EPS consensus estimates so they could pay $135+ for $LNTH and it's still accretive to earnings.
BTW, LNTH is a top 6 position in my investment portfolio along with CELH, SMCI, TDMX, FOUR and UBER.
Regards,
Jonah